179.90 -1.40 (-0.77%)
After hours: 7:31PM EDT
|Bid||179.90 x 800|
|Ask||181.30 x 100|
|Day's Range||181.00 - 188.20|
|52 Week Range||74.45 - 236.17|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 1, 2018 - May 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||220.78|
The company generated this revenue from research and development under a collaboration agreement with Novartis (NVS). In 2018, Akcea Therapeutics is expected to generate revenue of $71.3 million, while its peers Amgen (AMGN), Ionis Pharmaceuticals (IONS), and bluebird bio (BLUE) are expected to generate revenues of $22.5 billion, $582.4 million, and $23.9 million, respectively. In 2017, Akcea Therapeutics incurred research and development expenses of $126.8 million compared to $68.4 million in 2016.
Akcea Therapeutics (AKCA) is a late-stage biopharmaceutical company. AKCA’s pipeline includes volanesorsen, AKCEA-APO, AKCEA-ANGPTL, and AKCEA-APOCIII, which are based on Ionis Pharmaceuticals’ (IONS) antisense technology. In March 2018, two of the four analysts covering Akcea Therapeutics have given the stock “buy” or higher ratings, while two have given it “hold” ratings.
Bluebird bio Inc (NASDAQ: BLUE ), a clinical-stage biotechnology company that focuses on therapies for the treatment of severe diseases and cancer , released "highly encouraging" clinical data ...
Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics
Stock Monitor: bluebird bio Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 12, 2018 / Active-Investors.com has just released a free research report on InflaRx N.V. (NASDAQ: IFRX ). If you want ...
Healthcare sector has proven itself to be one of the most resilient sectors of the US economy. Since healthcare cannot be outsourced and represents an expense that people usually cut on last during economic downturns, investing in healthcare stocks is a good way to recession-proof your portfolio. Moreover, the sector itself is comprised of many […]
bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunothe
Shares of bluebird bio Inc (NASDAQ: BLUE ) gained more than 200 percent in value last year and investors can expect 2018 to be another "blue-ribbon year" for the stock, according to William ...
The recent volatility in the global stock market may make some investors feel queasy, but it is providing a buying opportunity in biotechnology stocks. Bhaman, whose fund received a 2018 U.S. Thomson Reuters Lipper Fund Award in the global large-cap growth fund category in New York on Tuesday, is focusing on companies such as Sage Therapeutics Inc (SAGE.O), Bluebird Bio Inc (BLUE.O) and Ionis Pharmaceuticals Inc (IONS.O) whose drugs can have multiple uses rather than pinpointing a specific ailment.
Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $2.52. The results missed Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment ...
bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2017.
bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today appointed Alison Finger as chief commercial officer.
Bagging the first breakthrough therapy designation for a sickle cell disease modifying treatment boosted confidence last month.
bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management team will present at the LEERINK Partners 7th Annual Global Healthcare Conference, Wednesday, February 14, at 3:00 p.m.
NEW YORK, Jan. 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Forward ...